Japan Grants Orphan Drug Designation to Rilzabrutinib for IgG4-Related Disease

The Ministry of Health, Labour and Welfare (MHLW) has officially granted orphan drug designation to rilzabrutinib, a novel oral treatment developed by Sanofi for IgG4-related disease (IgG4-RD). This designation is reserved for therapies addressing rare conditions with high unmet medical needs, providing a potential new path for patients in Japan facing this progressive chronic condition.

Understanding IgG4-RD

IgG4-related disease is a rare, immune-mediated condition where the immune system attacks various organs and tissues.

Impact: It can manifest in almost any organ, leading to severe inflammation, organ damage, and irreversible dysfunction.
Symptoms: Patients often experience “flares” or periods where symptoms significantly worsen.
Challenges: Due to its rarity, the global prevalence remains unknown, and diagnosis is frequently difficult.

How Rilzabrutinib Works

Rilzabrutinib (branded as Wayrilz in approved regions) is a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor.

Mechanism: It utilizes TAILORED COVALENCY® technology to selectively inhibit BTK, a protein expressed in B cells and macrophages that plays a central role in inflammatory pathways.
Goal: The therapy aims to restore immune balance through multi-immune modulation.

Clinical Evidence and Safety

The MHLW’s decision was supported by a Phase 2 study (NCT04520451) involving patients treated for 52 weeks.

Efficacy: Results presented at the 2025 European Alliance of Associations for Rheumatology congress showed a reduction in disease flares and markers, while also minimizing the need for glucocorticoids (steroids).
Safety Profile: No new safety signals were observed. Common adverse events (reported by >10% of participants) included diarrhea, COVID-19, dizziness, dry mouth, and nausea.
Next Steps: The drug is currently being evaluated in the RILIEF Phase 3 study (NCT07190196) for this indication.

Global Regulatory Status

Rilzabrutinib is rapidly expanding its footprint across several rare immune-mediated diseases.

Region	Status for Immune Thrombocytopenia (ITP)
US, EU, UAE	Approved (as of 2025)
Japan	Under Regulatory Review

Beyond ITP and IgG4-RD, the drug has received expedited designations for warm autoimmune hemolytic anemia (wAIHA) and sickle cell disease (SCD).